Literature DB >> 12095666

Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone.

Cliff Howells1, Steve Allen, John Gupta, Garry Stillwell, John Marsden, Michael Farrell.   

Abstract

This paper reports results from the first controlled trial of opioid withdrawal treatment in the UK using lofexidine in a prison setting. Seventy-four opioid dependent male inmates at a Southern England prison were randomised to receive either methadone (the standard prison treatment) or lofexidine using a randomised double-blind design. No significant statistical difference between the treatment groups was found in relation to the primary variable of severity of withdrawal symptoms (effect size=0.12). No discernible difference was found in the sitting blood pressure or heart rate of the two groups during the trial. These results provide support for the use of lofexidine for the management of opioid detoxification in the prison setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095666     DOI: 10.1016/s0376-8716(02)00024-8

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  17 in total

1.  Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.

Authors:  Nat M J Wright; Laura Sheard; Clive E Adams; Bruno J Rushforth; Wendy Harrison; Nicole Bound; Roger Hart; Charlotte N E Tompkins
Journal:  Br J Gen Pract       Date:  2011-12       Impact factor: 5.386

2.  Evidence-based addiction medicine: the use of lofexidine for opioid detoxification.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Olusanya Rufai
Journal:  Psychiatry (Edgmont)       Date:  2004-11

Review 3.  Non-commercial clinical trials of a medicinal product: can they survive the current process of research approvals in the UK?

Authors:  L Sheard; C N E Tompkins; N M J Wright; C E Adams
Journal:  J Med Ethics       Date:  2006-07       Impact factor: 2.903

4.  Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia.

Authors:  Jeffrey A Wickersham; Muhammad Muhsin Zahari; Marwan M Azar; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-02-13       Impact factor: 4.492

Review 5.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

Review 6.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

7.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

Review 8.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

9.  The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification.

Authors:  Laura Sheard; Nat M J Wright; Hany G El-Sayeh; Clive E Adams; Ryan Li; Charlotte N E Tompkins
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-02-05

10.  The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification.

Authors:  Laura Sheard; Nat M J Wright; Clive E Adams; Nicole Bound; Bruno Rushforth; Roger Hart; Charlotte N E Tompkins
Journal:  Trials       Date:  2009-07-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.